ストックスクリーナーアプリを入手
1.53
4.97%
-0.08
プレマーケット:
1.51
-0.02
-1.31%
前日終値:
$1.61
開ける：
$1.63
24時間の取引高:
1.08M
Relative Volume:
0.17
時価総額：
$431.44M
収益：
-
当期純損益:
$-225.14M
株価収益率:
-0.7806
EPS:
-1.96
ネットキャッシュフロー:
$-192.27M
1週間 パフォーマンス:
-10.53%
1か月 パフォーマンス:
-37.55%
6か月 パフォーマンス:
+96.08%
1年 パフォーマンス:
+0.66%
1日の値動き範囲:
$1.50
$1.63
1週間の範囲:
$1.46
$1.80
52週間の値動き範囲:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.53 | 454.00M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-22 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-26 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Invivyd Inc (IVVD) 最新ニュース
Invivyd, Inc. (NASDAQ:IVVD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Invivyd prices $125M stock offering at $2.50 per share - MSN
Analysts Offer Insights on Healthcare Companies: Invivyd (IVVD) and Pfizer (PFE) - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Invivyd stock amid FDA feedback - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial - Investing.com Nigeria
Invivyd receives FDA feedback on COVID antibody vs mRNA vaccine trial By Investing.com - Investing.com South Africa
Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy - Seeking Alpha
Invivyd aligns with FDA for Phase 3 vaccine trial - Traders Union
Invivyd rises on late-stage trial testing COVID antibody against mRNA vaccines - TradingView
Invivyd, Inc. Announces FDA Alignment on LIBERTY Phase 3 Clinical Trial for VYD2311, a Monoclonal Antibody Candidate for COVID-19 Prevention - Quiver Quantitative
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - The Manila Times
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 ... - Caledonian Record
FDA asks Invivyd to track myocarditis in new COVID antibody vs vaccine trial - Stock Titan
Invivyd Reports Strong Q3 Growth and Strategic Advances - MSN
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat
Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk - simplywall.st
Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Invivyd shares edge higher on education campaign with Olympic star Lindsey Vonn - MSN
HC Wainwright Predicts Invivyd FY2030 Earnings - MarketBeat
How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) - Yahoo Finance
H.C. Wainwright reaffirms Buy rating on Invivyd stock ahead of key trial data By Investing.com - Investing.com Nigeria
Aug Fed Impact: Should you avoid Invivyd Inc stock right now2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - baoquankhu1.vn
H.C. Wainwright reaffirms Buy rating on Invivyd stock ahead of key trial data - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Invivyd (IVVD), Alignment Healthcare (ALHC) - The Globe and Mail
Invivyd partners with ski champion Lindsey Vonn on antibody education By Investing.com - Investing.com Nigeria
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Invivyd partners with ski champion Lindsey Vonn on antibody education - Investing.com
Invivyd stock rises after partnering with Olympic champion Lindsey Vonn By Investing.com - Investing.com Canada
Invivyd partners with Lindsey Vonn to educate Americans on antibodies and disease prevention - marketscreener.com
Invivyd Announces Partnership with World Champion Skier - GlobeNewswire
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention - Finviz
Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential - Investing.com UK
Invivyd stock maintains Buy rating at BTIG on Long COVID treatment potential By Investing.com - Investing.com Nigeria
Invivyd to begin phase 2 trial of antibody therapy for long COVID - Investing.com Nigeria
Invivyd to begin phase 2 trial of antibody therapy for long COVID By Investing.com - Investing.com South Africa
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - The Manila Times
Invivyd Initiates Phase 2 Trial for VYD2311 Targeting Long COVID Patients - Intellectia AI
Experimental COVID antibody trial targets Long COVID and vaccine injury by 2026 - Stock Titan
Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Grows By 24.4% - MarketBeat
Bull Run: What is the target price for Invivyd Inc stockMarket Volume Summary & Safe Entry Trade Reports - baoquankhu1.vn
Invivyd, Inc.'s (NASDAQ:IVVD) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯
Invivyd Inc (IVVD) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):